C&L: Chemokine names new CEO

With its lead program poised to begin a Phase II study, Chemokine Therapeutics has named Walter Korz as its new president and CEO. Korz succeeds Bashir Jaffer who held the position as CEO on an interim basis since December 2007. Jaffer will continue to serve the company as chief financial officer. Report

Pharmacopeia said president and CEO Leslie Browne has resigned "to pursue other interests." Chairman Joseph Mollica has been appointment interim president and chief executive until a successor is named.

Aeterna Zentaris president and chief executive officer David Mazzo has resigned.

ArQule has appointed Paolo Pucci as chief executive officer and a member of the company's board of directors, effective June 9, 2008. Pucci succeeds Dr. Stephen Hill, who joined Solvay Pharmaceuticals as president and chief executive officer.

OncoVista Innovative Therapies has appointed Wolfram Rodatz as the new chief executive officer of AdnaGen.

Metabolex announced that Donald Hill has joined the company as chief financial officer. 

Taro Pharmaceutical Industries announced that Ron Kolker, C.P.A., has been appointed to the position of senior vice president, chief financial officer. 

Endo Pharmaceuticals Holdings has hired Ivan Gergel, M.D., as executive vice president, research and development. 

Galapagos NV named Dr. Piet Wigerinck senior vice president of development. 

Adolor Corporation named Eliseo Oreste Salinas, MD, MSc, as senior vice president research and development and chief medical officer. 

Amarillo Biosciences announced that Peter Mueller, Ph.D. has been appointed chief operating officer and director of research.

BioSante Pharmaceuticals announced the appointment of Michael Snabes, M.D., Ph.D. as vice president, clinical development.

Octagon Research Solutions has named John Rogers as director, Process Solutions.

Calibrant Biosystems announced the appointment of Dr. Satya Saxena as its vice-president of research.

Affymax named Carol Francisco, Ph.D. vice president, biostatistics and data management.

VioQuest Pharmaceuticals named Vernon Alvarez, Ph.D., vice president, research and development.

Genelabs Technologies declared on 14 April that Amy Patick PhD has been named by the company as vice president for biological sciences.

ADVENTRX Pharmaceuticals has appointed Jose Hechavarria to the new position of vice president of manufacturing.

Geneva Bioinformatics named Mark Pitman sales and business director, North America.

NextGen Bioscience said it appointed William Stimson of Scotland to its International Scientific Advisory Board.

Adnavance Technologies has appointed Kenneth Buechler, Ph.D., to its board of directors.

Tengion has appointed David Holveck to its board of directors.

Suggested Articles

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.

The takeover, the first of Paul Hudson’s time as CEO, will give Sanofi an IL-2 drug it thinks can become a foundation of future cancer combinations.